Results 1 to 10 of about 335,117 (337)

Molecular Mechanisms of Atopic Dermatitis Pathogenesis

International Journal of Molecular Sciences, 2021
Atopic dermatitis is a chronic, non-infectious inflammatory dermatosis. Acharacteristic feature is persistent itching of the skin. The chronic, relapsing course of the disease, economic burden, and the whole family’s involvement in the treatment process ...
Jowita Sroka-Tomaszewska, M. Trzeciak
semanticscholar   +1 more source

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

New England Journal of Medicine, 2021
BACKGROUND The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies,
T. Bieber, E. Simpson, J. Silverberg, D. Thaçi, C. Paul, A. Pink, Y. Kataoka, C. Chu, M. Dibonaventura, R. Rojo, J. Antinew, I. Ionita, R. Sinclair, S. Forman, Jacek Zdybski, P. Biswas, B. Malhotra, Fan Zhang, H. Valdez   +18 more
semanticscholar   +1 more source

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

JAMA dermatology, 2022
This analysis of 2 randomized clinical trials evaluates long-term (52 weeks) efficacy and safety of upadacitinib treatment in patients with atopic dermatitis.
E. Simpson, K. Papp, A. Blauvelt, C. Chu, H. Hong, N. Katoh, B. Calimlim, J. Thyssen, A. Chiou, R. Bissonnette, L. S. Stein Gold, C. Wegzyn, Xiaofei Hu, Meng Liu, John Liu, A. Tenorio, A. Chu, E. Guttman‐Yassky   +17 more
semanticscholar   +1 more source

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos, Baldrich, Esther Serra, Herráez, L., Jáuregui, Ignacio, Martín-Santiago, Ana, Ortiz de Frutos, Javier, Sastre, Joaquin, Silvestre, Juan Francisco, Universitat Autònoma de Barcelona, Valero, Antonio   +9 more
core   +3 more sources

Prevalence and Incidence of Atopic Dermatitis: A Systematic Review

Acta Dermato-Venereologica, 2020
The primary objective of this study was to systematically review and analyse epidemiological studies of the prevalence and incidence of atopic dermatitis (AD) during childhood and adulthood, focusing on data from the 21st century.
Simon B A Bylund, L. V. von Kobyletzki, Marika Svalstedt, Å. Svensson   +3 more
semanticscholar   +1 more source

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

British Journal of Dermatology, 2020
Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and
A. Wollenberg, A. Blauvelt, E. Guttman‐Yassky, M. Worm, C. Lynde, J. Lacour, L. Spelman, N. Katoh, H. Saeki, Yves Poulin, A. Lesiak, L. Kircik, S. H. Cho, P. Herranz, M. Cork, Ketty Peris, L. Steffensen, B. Bang, A. Kuznetsova, T. N. Jensen, M. L. Østerdal, E. Simpson   +21 more
semanticscholar   +1 more source

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

Journal of the European Academy of Dermatology and Venereology, 2020
Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective ...
A. Wollenberg, S. Christen-Zäch, Alain Taïeb, Carle Paul, J. P. Thyssen, M. Bruin-Weller, C. Vestergaard, J. Seneschal, T. Werfel, M. Cork, B. Kunz, R. Fölster-Holst, M. Trzeciak, U. Darsow, Z. Szalai, M. Deleuran, L. Kobyletzki, L. Kobyletzki, S. Barbarot, A. Heratizadeh, U. Gieler, D. Hijnen, S. Weidinger, L. Raeve, Å. Svensson, D. Simon, J. Stalder, J. Ring   +27 more
semanticscholar   +1 more source

The course of life of patients with childhood atopic dermatitis [PDF]

, 2009
Atopic dermatitis mainly covers the period of infancy to adulthood, an important period in the development of an individual. The impairment of quality of life and the psychological wellbeing of children with atopic dermatitis have been well documented ...
Abeni, Absolon, Beattie, Ben-Gashir, Ben-Gashir, Bender, Bos, Buske-Kirschbaum, Carroll, Chamlin, Chamlin, Evers, Finlay, Garber, Ginsburg, Grootenhuis, Grootenhuis, Groothoff, Haavet, Hanifin, Hashiro, Holm, Kelsay, Kiebert, Last, Leung, Levy, Lewis, Lewis-Jones, Lewis-Jones, Lundberg, Reuveni, Sampogna, Schmid-Ott, Seiffert, Spergel, Stam, Stam, Sturgill, Terreehorst, Williams, Williams, Wittkowski   +42 more
core   +4 more sources

Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis

International Journal of Molecular Sciences, 2020
Atopic dermatitis (AD) is a common and relapsing skin disease that is characterized by skin barrier dysfunction, inflammation, and chronic pruritus. While AD was previously thought to occur primarily in children, increasing evidence suggests that AD is ...
Gabsik Yang, J. Seok, H. Kang, Yong-Yeon Cho, H. Lee, Joo Young Lee   +5 more
semanticscholar   +1 more source

Role of genetic aspect in pathogenesis of atopic dermatitis [PDF]

, 2013
The pathogenesis of atopic dermatitis (AD) is a very complicated process that involves an intricate array of molecules. Nowadays it is generally accepted that cytokines play an important role in the progression of the clinical presentation of atopic ...
Wesserling Martyna
core   +1 more source